Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note released on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group raised shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 target price for the company in a report on Thursday, July 11th.

Brainstorm Cell Therapeutics Price Performance

Shares of BCLI stock opened at $2.33 on Tuesday. The company has a market cap of $163.29 million, a price-to-earnings ratio of -6.94 and a beta of 0.33. Brainstorm Cell Therapeutics has a 1 year low of $2.01 and a 1 year high of $11.89. The firm has a fifty day moving average price of $0.44 and a 200-day moving average price of $0.46.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). During the same period in the prior year, the business posted ($0.27) EPS. Equities research analysts expect that Brainstorm Cell Therapeutics will post -0.19 EPS for the current year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.